Adds proprietary CAR sequence IP to Liberate’s selective in vivo delivery platform, strengthening the foundation of its emerging CAR-M therapeutic classCAMBRIDGE, Mass.--(BUSINESS WIRE)--Liberate Bio, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results